# Study to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General Anaesthesia

> **NCT02481791** · PHASE3 · UNKNOWN · sponsor: **Alder Hey Children's NHS Foundation Trust** · enrollment: 35 (estimated)

## Conditions studied

- Children
- Heart Diseases
- Anaesthesia
- Magnetic Resonance Imaging

## Interventions

- **DRUG:** Remifentanil and/or propofol
- **DRUG:** Remifentanil and/or propofol
- **DRUG:** propofol

## Key facts

- **NCT ID:** NCT02481791
- **Lead sponsor:** Alder Hey Children's NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-07
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02481791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02481791, "Study to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General Anaesthesia". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02481791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*